ClinicalTrials.Veeva

Menu

REtinal Detachment Outcomes Study (REDOS)

L

Laval University

Status

Enrolling

Conditions

Retinal Detachment

Treatments

Procedure: Pars plana vitrectomy with scleral buckle
Other: Sulfur hexafluoride gas tamponade
Procedure: Pars plana vitrectomy
Other: Perfluoropropane gas

Study type

Interventional

Funder types

Other

Identifiers

NCT05863312
2023-6508

Details and patient eligibility

About

Background: Few large randomized controlled trials provide strong evidence to guide surgical repair of primary rhegmatogenous retinal detachment (RRD) repair. The purpose of this factorial, single-blind, randomized controlled trial is to analyze and compare the surgical outcomes, functional visual outcomes, complications, and quality of life associated with RRD repair using (A) pars plana vitrectomy only (PPV) or PPV with scleral buckle (PPV-SB) and (B) sulfur hexafluoride gas (SF6) or perfluoropropane gas (C3F8) tamponade.

Methods: Eligible patients with moderately complex RRD will be randomized 1:1 to PPV or PPV-SB and 1:1 to SF6 or C3F8 gas tamponade. Approximately 560 patients will be recruited to be able to detect a difference of around 10% in SSAS rate between groups. Patients will be followed using multimodal imaging and quality of life questionnaires before and after the surgical repair until 1 year postoperative. The primary outcome will be single surgery anatomic success (SSAS), defined as absence of reoperation for recurrent RRD in the operating room. Secondary outcomes will be pinhole visual acuity (PHVA) at 8-10 weeks and 6 months, final best-corrected visual acuity (BCVA), final retina status (i.e., attached or detached), time to onset of RRD recurrence, severity and number of complications, and questionnaire results.

Discussion: This will be the first 2 × 2 factorial randomized controlled trial examining repair techniques in primary RRD. It will also be the first randomized controlled trial to compare gas tamponade between the two most common agents. Notably, it will be adequately powered to detect a clinically significant effect size. The use of multimodal imaging will also be a novel aspect of this study, allowing us to compare head-to-head the impact of adding an SB to the retina's recovery after RRD repair and of differing gas tamponades. Until now, the treatment of RRD has been largely guided by pragmatic retrospective cohort studies. There is a lack of strong evidence guiding therapeutic decisions and this trial will address (1) whether supplemental SB is justified and (2) whether longer duration gas tamponade with C3F8 is necessary.

Enrollment

560 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

  • Age ≥18 years
  • Diagnosis of rhegmatogenous retinal detachment

Exclusion Criteria, retinal detachment with:

  • Proliferative vitreoretinopathy (PVR) grade ≥C2
  • Chronic RRD with duration >3 months
  • Proliferative diabetic retinopathy with tractional retinal detachment (RD)
  • Macular holes
  • Epiretinal membrane grade 3 or 4
  • Traumatic RD
  • Giant retinal tears
  • Retinal dialysis
  • Foveoschisis
  • Wet age-related macular degeneration
  • Endophthalmitis
  • Acute retinal necrosis
  • Coats disease
  • Retinopathy of prematurity
  • Retinoschisis
  • Retinal colobomas
  • Prior glaucoma surgery or strabismus surgery (favoring PPV only)
  • Superior RD extent less than 3 clock hours (favoring PPV only)

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Factorial Assignment

Masking

Triple Blind

560 participants in 4 patient groups

Pars plana vitrectomy + sulfur hexafluoride gas tamponade
Active Comparator group
Treatment:
Procedure: Pars plana vitrectomy
Other: Sulfur hexafluoride gas tamponade
Pars plana vitrectomy with scleral buckle + sulfur hexafluoride gas tamponade
Experimental group
Treatment:
Other: Sulfur hexafluoride gas tamponade
Procedure: Pars plana vitrectomy with scleral buckle
Pars plana vitrectomy + perfluoropropane gas tamponade
Experimental group
Treatment:
Other: Perfluoropropane gas
Procedure: Pars plana vitrectomy
Pars plana vitrectomy with scleral buckle + perfluoropropane gas tamponade
Experimental group
Treatment:
Other: Perfluoropropane gas
Procedure: Pars plana vitrectomy with scleral buckle

Trial contacts and locations

1

Loading...

Central trial contact

Julie Mauger, BSc

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems